1. Home
  2. SMWB vs LRMR Comparison

SMWB vs LRMR Comparison

Compare SMWB & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Similarweb Ltd.

SMWB

Similarweb Ltd.

HOLD

Current Price

$2.75

Market Cap

240.7M

Sector

Technology

ML Signal

HOLD

Logo Larimar Therapeutics Inc.

LRMR

Larimar Therapeutics Inc.

HOLD

Current Price

$4.47

Market Cap

280.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SMWB
LRMR
Founded
2007
N/A
Country
Israel
United States
Employees
N/A
N/A
Industry
Computer Software: Programming Data Processing
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
240.7M
280.0M
IPO Year
2021
2014

Fundamental Metrics

Financial Performance
Metric
SMWB
LRMR
Price
$2.75
$4.47
Analyst Decision
Buy
Strong Buy
Analyst Count
7
7
Target Price
$8.13
$16.29
AVG Volume (30 Days)
1.7M
7.1M
Earning Date
01-01-0001
04-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$11.11
N/A
Revenue Next Year
$11.13
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.22
$1.61
52 Week High
$10.75
$6.42

Technical Indicators

Market Signals
Indicator
SMWB
LRMR
Relative Strength Index (RSI) 33.12 48.96
Support Level $2.46 $3.10
Resistance Level $2.97 $5.37
Average True Range (ATR) 0.18 0.63
MACD 0.12 -0.09
Stochastic Oscillator 57.98 29.43

Price Performance

Historical Comparison
SMWB
LRMR

About SMWB Similarweb Ltd.

Similarweb Ltd provides digital data and analytics that power critical business decisions. The group recognizes revenue from subscriptions to the platform and other subscription products on a straight-line basis over the term of the contract subscription period beginning on the date access to the platform is granted, provided all other revenue recognition criteria have been met. It has geographic presence in Israel, the United States, the United Kingdom, Asia Pacific, Europe, and Other. The group generates the majority of its revenue from the United States.

About LRMR Larimar Therapeutics Inc.

Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.

Share on Social Networks: